Specialty Pharmacy

FDA officials based their approval on the review of data and evidence that demonstrated a close similarity between pegfilgrastim-apgf and its reference product.

Ripretinib is a kinase inhibitor indicated for adults with advanced GIST, approved by the FDA in May 2020.

Apalutamide in combination with ADT prolonged median OS by 14 months and decreased the risk of death by 22%. Further, median OS was significantly longer, with 73.9 months for patients receiving treatment with apalutamide in combination with ADT compared with 59.9 months for patients receiving placebo in combination with ADT.

Interventions such as exercise programs and discharge planning efforts have been promising in addressing functional impairment and improving post-discharge outcomes.

Tildrakizumab is an IL-23 inhibitor indicated for adults with moderate-to-severe plaque psoriasis and is under investigation for PsA.

According to a recent study, diet can affect the outcome of chemotherapy due to microbes in the gut that can trigger changes in a patient’s response to drugs.

In the new data cut-offs from both studies, the survival advantages for the combination with fulvestrant and combination with an aromatase inhibitor were shown, but major disadvantages were also evident, according to the IQWiG.

The COVID-19 pandemic rapidly pushed traditional face-to-face instruction within schools of pharmacy into a fully remote learning environment.

Mitapivat is an investigational, oral, small molecule allosteric activator of wild-type and a variety of mutated PKR enzymes that is not yet approved by the FDA.

IVLBCL is a rare subtype of lymphoma that is particularly hard to diagnose due to a lack of swelling or enlargement of the lymph nodes.

Investigators found that less than a quarter of study participants with colorectal cancer were taking their medications as prescribed, suggesting that many could benefit from improved adherence.

According to a recent study, olanzapine may help patients with advanced cancer manage symptoms unrelated to chemotherapy, such as nausea and vomiting.

Specialty pharmacy is beginning to implement its own set of strategies in order to manage the cost of one of the most expensive sectors of the pharmaceutical industry.

Telemedicine and connected devices are emerging as technologies to provide greater access and convenience to care for those who can defer treatment by way of an in-person consultation.

At the 2020 American Society of Clinical Oncology Virtual Scientific Program, researchers presented a recent study that is the largest to date analyzing CLL treatment patterns among VHA patients between 2013 and 2018.

Trastuzumab deruxtecan (T-DXd) (Enhertu) demonstrated strong efficacy in a phase 2 trial for treatment of HER2-positive metastatic breast cancer.

Treatment with avelumab (Bavencio) potentially cured 8 of 15 women in a trial with gestational trophoblastic tumors resistant to single-agent chemotherapy.

Ensuring patients continue receiving life-sustaining home infusions that were traditionally administered in the hospital or hospital clinic settings is of the upmost importance.

Atezolizumab (Tecentriq) approved in combination with bevacizumab (Avastin) for the treatment of patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.

In 2017 alone, there was an estimated 785 fewer cancer deaths in states that adopted Medicaid expansion.

At 5 years follow up, the data showed that the OS for women on olaparib was 42.1%, while the placebo OS was 33.2%.

Artificial intelligence will inevitably play a major role in hub services, improving efficiency and speed to therapy.

FDA has granted Fast Track designation to Cardiff Oncology’s onvansertib, an oral and highly-selective Polo-like Kinase 1 (PLK1) inhibitor, for the second-line treatment of patients with KRAS-mutated metastatic colorectal cancer.

Pharma companies that shift their attention to what providers, payers, and patients are asking for will profit from the growing worldwide market on preventative care.

In an era of high-priced drugs, health care stakeholders continue to explore alternative pricing models that focus on the concept of value-based drug purchasing models.

The therapy is approved for patients with squamous or non-squamous disease and regardless of programmed death-ligand 1 (PD-L1) expression.

The National Home Infusion Foundation (NHIF) announced yesterday that the winner of the 2020 Outstanding Abstract Achievement Award is Rachel Dellevar, PharmD.

According to the study authors, patients with MS who underwent the 4-week mindfulness training not only showed greater improvement in processing speed and regulating negative emotions than those who did not participate in any training, but they also improved compared with those who tried adaptive cognitive training (ACT).